JP2018505658A5 - - Google Patents

Download PDF

Info

Publication number
JP2018505658A5
JP2018505658A5 JP2017530266A JP2017530266A JP2018505658A5 JP 2018505658 A5 JP2018505658 A5 JP 2018505658A5 JP 2017530266 A JP2017530266 A JP 2017530266A JP 2017530266 A JP2017530266 A JP 2017530266A JP 2018505658 A5 JP2018505658 A5 JP 2018505658A5
Authority
JP
Japan
Prior art keywords
gene
tumor
rna
score
genes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017530266A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018505658A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/064445 external-priority patent/WO2016094377A1/en
Publication of JP2018505658A publication Critical patent/JP2018505658A/ja
Publication of JP2018505658A5 publication Critical patent/JP2018505658A5/ja
Pending legal-status Critical Current

Links

JP2017530266A 2014-12-09 2015-12-08 Pd−1アンタゴニストに対する応答の遺伝子シグネチャーバイオマーカーを得るための系および方法 Pending JP2018505658A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462089538P 2014-12-09 2014-12-09
US62/089,538 2014-12-09
US201562160284P 2015-05-12 2015-05-12
US62/160,284 2015-05-12
PCT/US2015/064445 WO2016094377A1 (en) 2014-12-09 2015-12-08 System and methods for deriving gene signature biomarkers of response to pd-1 antagonists

Publications (2)

Publication Number Publication Date
JP2018505658A JP2018505658A (ja) 2018-03-01
JP2018505658A5 true JP2018505658A5 (enExample) 2018-12-27

Family

ID=56108044

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017530266A Pending JP2018505658A (ja) 2014-12-09 2015-12-08 Pd−1アンタゴニストに対する応答の遺伝子シグネチャーバイオマーカーを得るための系および方法

Country Status (11)

Country Link
US (1) US11377693B2 (enExample)
EP (1) EP3230498B1 (enExample)
JP (1) JP2018505658A (enExample)
KR (1) KR20170086661A (enExample)
CN (1) CN107109700A (enExample)
AU (2) AU2015360736A1 (enExample)
BR (1) BR112017012222A2 (enExample)
CA (1) CA2968406A1 (enExample)
MX (1) MX2017007535A (enExample)
RU (1) RU2017123117A (enExample)
WO (1) WO2016094377A1 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5603012B2 (ja) 2005-12-02 2014-10-08 トヘ モウント シナイ スクール オフ メディシネ オフ ニューヨーク ウニベルシトイ 非天然表面タンパク質を提示するキメラウイルス及びその使用
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
PE20151921A1 (es) 2013-03-14 2015-12-26 Icahn School Med Mount Sinai Virus de la enfermedad de newcastle y usos de los mismos
CR20160319A (es) 2013-12-12 2016-11-08 Jiangsu Hengrui Medicine Co Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este
AU2015222685A1 (en) 2014-02-27 2016-09-08 Viralytics Limited Combination method for treatment of cancer
JP6767096B2 (ja) * 2014-12-11 2020-10-14 リティックス バイオファーマ エイエス 免疫チェックポイント阻害剤の組み合わせ
WO2016168133A1 (en) 2015-04-17 2016-10-20 Merck Sharp & Dohme Corp. Blood-based biomarkers of tumor sensitivity to pd-1 antagonists
US11337969B2 (en) 2016-04-08 2022-05-24 X4 Pharmaceuticals, Inc. Methods for treating cancer
US10438699B2 (en) * 2016-05-10 2019-10-08 Macau University Of Science And Technology Method and system for determining an association of biological features with a medical condition
JP7295015B2 (ja) 2016-10-07 2023-06-20 オムニセック インコーポレイテッド 個別化治療を決定するための方法
US20190376146A1 (en) * 2016-11-24 2019-12-12 Daiichi Sankyo Company, Limited Method for predicting sensitivity of cancer to treatment with pd-1 immune checkpoint inhibitor
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
JP2021521439A (ja) * 2018-04-13 2021-08-26 エックス4 ファーマシューティカルズ, インコーポレイテッド がん血清バイオマーカーおよびその使用方法
WO2019213478A1 (en) 2018-05-04 2019-11-07 Nanostring Technologies, Inc. Gene expression assay for measurement of dna mismatch repair deficiency
WO2019222075A1 (en) 2018-05-14 2019-11-21 Merck Sharp And Dohme Corp. Biomarkers for a combination therapy comprising lenvatinib and a pd-1 antagonist
US20210363590A1 (en) * 2018-05-21 2021-11-25 Nanostring Technologies, Inc. Molecular gene signatures and methods of using same
WO2020005068A2 (en) * 2018-06-29 2020-01-02 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Gene signatures and method for predicting response to pd-1 antagonists and ctla-4 antagonists, and combination thereof
EP3837277A4 (en) 2018-08-17 2022-05-11 Icahn School of Medicine at Mount Sinai RECOMBINANT NEWCASTLE DISEASE VIRUSES AND THEIR USES IN THE PREVENTION OF RSV DISEASE OR HUMAN METAPNEUMOVIRUS INFECTION
MX2021006578A (es) * 2018-12-05 2021-07-07 Genentech Inc Procedimientos de diagnostico y composiciones para la inmunoterapia contra el cancer.
JP2022534982A (ja) * 2019-05-30 2022-08-04 ブリストル-マイヤーズ スクイブ カンパニー 細胞局在化シグネチャーおよびその使用
WO2021030156A1 (en) * 2019-08-09 2021-02-18 The Regents Of The University Of California Compositions and methods for diagnosis and treatment of bladder cancer
CN114761012B (zh) 2019-09-24 2025-03-21 米拉蒂治疗股份有限公司 组合疗法
WO2021091747A1 (en) * 2019-11-04 2021-05-14 Merck Sharp & Dohme Corp. ANGIOGENESIS AND mMDSC GENE EXPRESSION BASED BIOMARKER OF TUMOR RESPONSE TO PD-1 ANTAGONISTS
WO2021110927A1 (en) * 2019-12-04 2021-06-10 Servicio Andaluz De Salud Method to predict the response to cancer treatment with anti-pd1 immunotherapy
CN111088360A (zh) * 2020-01-17 2020-05-01 暨南大学 Pd1-ctla4和/或pdl2-ctla4在制备预测aml预后试剂盒中的应用
CN115515585A (zh) 2020-03-10 2022-12-23 X4 制药有限公司 用于治疗中性粒细胞减少症的方法
WO2022059785A1 (ja) * 2020-09-18 2022-03-24 小野薬品工業株式会社 免疫チェックポイント阻害剤に対する応答を予測する方法
EP4225950A4 (en) * 2020-10-05 2025-02-26 4C Biomed Limited Marker for response to pd-1/pd-l1 immunotherapy
WO2022135402A1 (zh) * 2020-12-24 2022-06-30 信达生物制药(苏州)有限公司 Pd-l1和/或mhc-2生物标记物在预测肺癌患者治疗疗效中的用途
JP2024526977A (ja) * 2021-07-22 2024-07-19 アシリア ダイアグノスティックス ベースローテン フェンノートシャップ 免疫療法後の治療反応のためのバイオマーカー
IL314037A (en) 2022-01-03 2024-09-01 Checkmate Pharmaceuticals Inc Transcriptional biomarkers for response to innate immune activators
EP4540418A4 (en) * 2022-06-17 2026-07-22 Merck Sharp & Dohme Llc Genome-wide tumor-derived gene expression signatures associated with a poor prognosis for melanoma patients with early-stage disease
WO2024083867A1 (en) 2022-10-17 2024-04-25 Ultimovacs Asa Biomarker
EP4623092A1 (en) * 2022-11-21 2025-10-01 Merck Sharp & Dohme LLC Genome wide tumor derived gene expression based signatures associated with poor prognosis for melanoma patients with early stage disease
JPWO2024225488A1 (enExample) * 2023-04-27 2024-10-31
WO2025034883A1 (en) 2023-08-08 2025-02-13 Quanta Therapeutics, Inc. Combination therapies with kras modulators
WO2025106905A1 (en) 2023-11-17 2025-05-22 Quanta Therapeutics, Inc. Combination therapies with a kras modulator and an immunomodulator inhibitor
WO2025136845A1 (en) * 2023-12-19 2025-06-26 Merck Sharp & Dohme Llc Methods of treating a patient with a pd-1 antagonist
WO2026060384A1 (en) 2024-09-16 2026-03-19 Quanta Therapeutics, Inc. Combination therapies with kras modulators

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5202231A (en) 1987-04-01 1993-04-13 Drmanac Radoje T Method of sequencing of genomes by hybridization of oligonucleotide probes
US5525464A (en) 1987-04-01 1996-06-11 Hyseq, Inc. Method of sequencing by hybridization of oligonucleotide probes
US5700637A (en) 1988-05-03 1997-12-23 Isis Innovation Limited Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
GB8822228D0 (en) 1988-09-21 1988-10-26 Southern E M Support-bound oligonucleotides
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5547839A (en) 1989-06-07 1996-08-20 Affymax Technologies N.V. Sequencing of surface immobilized polymers utilizing microflourescence detection
US5242974A (en) 1991-11-22 1993-09-07 Affymax Technologies N.V. Polymer reversal on solid surfaces
US5424186A (en) 1989-06-07 1995-06-13 Affymax Technologies N.V. Very large scale immobilized polymer synthesis
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US5527681A (en) 1989-06-07 1996-06-18 Affymax Technologies N.V. Immobilized molecular synthesis of systematically substituted compounds
DE3924454A1 (de) 1989-07-24 1991-02-07 Cornelis P Prof Dr Hollenberg Die anwendung von dna und dna-technologie fuer die konstruktion von netzwerken zur verwendung in der chip-konstruktion und chip-produktion (dna chips)
EP0430881A3 (en) 1989-11-29 1991-10-23 Ciba-Geigy Ag Photochromic compounds, process for their preparation and their use
US5288644A (en) 1990-04-04 1994-02-22 The Rockefeller University Instrument and method for the sequencing of genome
US5412087A (en) 1992-04-24 1995-05-02 Affymax Technologies N.V. Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces
US5324633A (en) 1991-11-22 1994-06-28 Affymax Technologies N.V. Method and apparatus for measuring binding affinity
US5384261A (en) 1991-11-22 1995-01-24 Affymax Technologies N.V. Very large scale immobilized polymer synthesis using mechanically directed flow paths
JP2775346B2 (ja) 1992-04-03 1998-07-16 アプライド バイオシステムズ,インコーポレイテッド プローブ構成物および方法
US5554501A (en) 1992-10-29 1996-09-10 Beckman Instruments, Inc. Biopolymer synthesis using surface activated biaxially oriented polypropylene
US5503980A (en) 1992-11-06 1996-04-02 Trustees Of Boston University Positional sequencing by hybridization
DE4311230C2 (de) 1993-04-02 1996-12-19 Mannesmann Ag Nicht-spurgebundenes Fahrzeug mit Elektromotor
US5837832A (en) 1993-06-25 1998-11-17 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
US5472672A (en) 1993-10-22 1995-12-05 The Board Of Trustees Of The Leland Stanford Junior University Apparatus and method for polymer synthesis using arrays
US5470710A (en) 1993-10-22 1995-11-28 University Of Utah Automated hybridization/imaging device for fluorescent multiplex DNA sequencing
US6156501A (en) 1993-10-26 2000-12-05 Affymetrix, Inc. Arrays of modified nucleic acid probes and methods of use
US5429807A (en) 1993-10-28 1995-07-04 Beckman Instruments, Inc. Method and apparatus for creating biopolymer arrays on a solid support surface
US5631734A (en) 1994-02-10 1997-05-20 Affymetrix, Inc. Method and apparatus for detection of fluorescently labeled materials
US5571639A (en) 1994-05-24 1996-11-05 Affymax Technologies N.V. Computer-aided engineering system for design of sequence arrays and lithographic masks
US5556752A (en) 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
US5624711A (en) 1995-04-27 1997-04-29 Affymax Technologies, N.V. Derivatization of solid supports and methods for oligomer synthesis
US5545531A (en) 1995-06-07 1996-08-13 Affymax Technologies N.V. Methods for making a device for concurrently processing multiple biological chip assays
US5661028A (en) 1995-09-29 1997-08-26 Lockheed Martin Energy Systems, Inc. Large scale DNA microsequencing device
US6022963A (en) 1995-12-15 2000-02-08 Affymetrix, Inc. Synthesis of oligonucleotide arrays using photocleavable protecting groups
CA2702219C (en) 1996-11-06 2013-01-08 Sequenom, Inc. High density immobilization of nucleic acids
DE69706187T2 (de) 1996-11-06 2002-04-11 Sequenom, Inc. Zusammensetzungen und verfahren zur immobilisierung von nukleinsäure auf festträgern
US6077674A (en) 1999-10-27 2000-06-20 Agilent Technologies Inc. Method of producing oligonucleotide arrays with features of high purity
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
CA2566519C (en) * 2004-05-14 2020-04-21 Rosetta Genomics Ltd. Micrornas and uses thereof
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
WO2009061800A2 (en) * 2007-11-09 2009-05-14 Genentech, Inc. Methods and compositions for diagnostic use in cancer patients
WO2010098788A2 (en) 2008-08-25 2010-09-02 Amplimmune, Inc. Pd-i antagonists and methods for treating infectious disease
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
WO2011094483A2 (en) * 2010-01-29 2011-08-04 H. Lee Moffitt Cancer Center And Research Institute, Inc. Immune gene signatures in cancer
WO2012135408A1 (en) 2011-03-31 2012-10-04 Merck Sharp & Dohme Corp. Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments
BR112014002353B1 (pt) 2011-08-01 2022-09-27 Genentech, Inc Usos de antagonistas de ligação do eixo pd-1 e inibidores de mek, composições farmacêuticas, e kit
SG11201402490XA (en) * 2011-11-23 2014-06-27 Amgen Inc Methods of treatment using an antibody against interferon gamma
JP6923291B2 (ja) 2012-07-12 2021-08-18 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 少なくとも7個の遺伝子のサインを用いて、固形癌を患う患者の生存期間および処置に対する応答性を予測するための方法
WO2014015011A1 (en) * 2012-07-19 2014-01-23 Tensorcom, Inc. Method and apparatus for the alignment of a 60 ghz endfire antenna
US10626463B2 (en) 2012-08-03 2020-04-21 Icahn School Of Medicine At Mount Sinai Biomarker associated with risk of melanoma reoccurrence
KR20150131269A (ko) 2013-03-15 2015-11-24 제넨테크, 인크. Pd-1 및 pd-l1 관련 상태를 치료하기 위한 바이오마커 및 방법
WO2014194293A1 (en) 2013-05-30 2014-12-04 Amplimmune, Inc. Improved methods for the selection of patients for pd-1 or b7-h4 targeted therapies, and combination therapies thereof
EP3084003A4 (en) 2013-12-17 2017-07-19 Merck Sharp & Dohme Corp. Ifn-gamma gene signature biomarkers of tumor response to pd-1 antagonists
US20160312295A1 (en) 2013-12-17 2016-10-27 Merck Sharp & Dohme Corp. Gene signature biomarkers of tumor response to pd-1 antagonists
WO2015094996A2 (en) 2013-12-17 2015-06-25 Merck Sharp & Dohme Corp. Pd-l1 gene signature biomarkers of tumor response to pd-1 antagonists
WO2016168133A1 (en) 2015-04-17 2016-10-20 Merck Sharp & Dohme Corp. Blood-based biomarkers of tumor sensitivity to pd-1 antagonists

Similar Documents

Publication Publication Date Title
Mohan et al. Profiling of circulating free DNA using targeted and genome-wide sequencing in patients with SCLC
Chen et al. Immunological network analysis in HPV associated head and neck squamous cancer and implications for disease prognosis
Zhao et al. Levels of plasma Epstein-Barr virus DNA prior and subsequent to treatment predicts the prognosis of nasopharyngeal carcinoma
Wong et al. Poor survival with wild-type TP53 ovarian cancer?
RU2017123117A (ru) Система и способы получения биомаркеров генных сигнатур ответа на антагонисты pd-1
Ramaker et al. RNA sequencing-based cell proliferation analysis across 19 cancers identifies a subset of proliferation-informative cancers with a common survival signature
Wang et al. Profiling plasma microRNA in nasopharyngeal carcinoma with deep sequencing
JP2017508970A5 (enExample)
CN103733065A (zh) 用于癌症的分子诊断试验
JP2017529859A5 (enExample)
Popovici et al. Selecting control genes for RT-QPCR using public microarray data
CN113444804B (zh) 宫颈癌预后相关基因及其在制备宫颈癌预后预测诊断产品中的应用
CN112908470A (zh) 一种基于rna结合蛋白基因的肝细胞癌预后评分系统及其应用
CN108277278A (zh) 一种用于正常核型急性髓系白血病预后分层的方法及装置
JP2018527886A5 (enExample)
JP2016073287A (ja) 腫瘍特性及びマーカーセットの同定のための方法、腫瘍分類、並びに癌のマーカーセット
CN106148529A (zh) 与胃癌相关的LncRNA标记物及其专用检测引物、检测方法、试剂盒与应用
JP2016515800A5 (enExample)
Greenberg et al. Developing a predictive model for metastatic potential in pancreatic neuroendocrine tumor
CN109880905A (zh) 一组用于三阴性乳腺癌免疫组化分型的基因及其应用
Miliotis et al. Determinants of gastric cancer immune escape identified from non-coding immune-landscape quantitative trait loci
Shen et al. Predicting the immune landscape of invasive breast carcinoma based on the novel signature of immune‐related lncRNA
CN107653312B (zh) 与血脂水平和冠心病相关的rs7901016检测系统及相关应用
Munkácsy et al. Gene expression-based prognostic and predictive tools in breast cancer
CN108913773A (zh) 一种临床评价卵巢癌铂类药物化疗敏感性的多分子标志物及其装置与评价方法